The role of apolipoprotein E in lipid metabolism in the central nervous system

Cellular and Molecular Life Sciences

Volumn 61, Issue 15, 2004, Pages 1896-1906

  Han, X ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Apolipoprotein E; Cholesterol; Electrospray ionization mass spectrometry; Lipidomics; Phospholipids; Sulfatide

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; PHOSPHOLIPID; POLYUNSATURATED FATTY ACID; SULFATIDE;

CELL MEMBRANE; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; HOMEOSTASIS; HUMAN; LIPID METABOLISM; METABOLISM; MOLECULE; NEUROBIOLOGY; NONHUMAN; PHENOTYPE; PLASMA; REVIEW;

EID: 4143115606     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-004-4009-z     Document Type: Review

References (123)

1. Mackness M. I. and Durrington P. N. (1992) Lipoprotein separation and analysis for clinical studies. In: Lipoprotein Analysis: A Practical Approach, pp. 1-42, Converse C. A. and Skinner E. R. (eds), Oxford University Press, New York
2. Brown M. S. and Goldstein J. L. (1986) A receptor-mediated pathway for cholesterol homeostasis. Science 232: 34-47
3. Fredenrich A. and Bayer P. (2003) Reverse cholesterol transport, high density lipoproteins and HDL cholesterol: recent data. Diabetes Metab. 29: 201-205
4. Rader D. J. (2003) Regulation of reverse cholesterol transport and clinical implications. Am. J. Cardiol. 92: 42J-49J
5. Wang M. and Briggs M. R. (2004) HDL: The metabolism, function and therapeutic importance. Chem. Rev. 104: 119-137
6. Ladu M. J., Reardon C., van Eldik L., Fagan A. M., Bu G., Holtzman D. M. et al. (2000) Lipoproteins in the central nervous system. Ann. N. Y. Acad. Sci. 903: 167-175
7. Koch S., Donarski N., Goetze K., Kreckel M., Stuerenburg H.-J., Buhmann C. et al. (2001) Characterization of four lipoprotein classes in human cerebrospinal fluid. J. Lipid Res. 42: 1143-1151
8. Rebeck G. W., Reiter J. S., Strickland D. K. and Hyman B. T. (1993) Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 11: 575-580
9. Li W. H., Tanimura M., Luo C. C., Datta S. and Chan L. (1988) The apolipoprotein multigene family: biosynthesis, structure, structure-function relationships and evolution. J. Lipid Res. 29: 245-271
10. Danik M., Champagne D., Petit-Turcotte C., Beffert U. and Poirier J. (1999) Brain lipoprotein metabolism and its relation to neurodegenerative disease. Crit. Rev. Neurobiol. 13: 357-407
11. de Knijff P., van den Maagdenberg A. M. J. M., Frants R. R. and Havekes L. M. (1994) Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels. Hum. Mutat. 4: 178-194
12. Nickerson D. A., Taylor S. L., Fullerton S. M., Weiss K. M., Clark A. G., Stengard J. H. et al. (2000) Sequence diversity and large-scale typing of SNPs in the human apolipoprotein E gene. Genome Res. 10: 1532-1545
13. Laws S. M., Hone E., Gandy S. and Martins R. N. (2003) Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J. Neurochem. 84: 1215-1236
14. Mahley R. W. (1988) Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 240: 622-630
15. Smith J. (2002) Apolipoproteins and aging: emerging mechanisms. Ageing Res. Rev. 1: 345-365
16. Lin C. T., Xu Y., Wu J. Y. and Chan L. (1986) Immunoreactive apolipoprotein E is a widely distributed cellular protein. Immunohistochemical localization of apolipoprotein E in baboon tissues. J. Clin. Invest. 78: 947-958
17. Elshourbagy N. A., Liao W. S., Mahley R. W. and Taylor J. M. (1985) Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc. Natl. Acad. Sci. USA 82: 203-207
18. Srivastava R. A. K., Bhasin N. and Srivastava N. (1996) Apolipoprotein E gene expression in various tissues of mouse and regulation by estrogen. Biochem. Mol. Biol. Int. 38: 91-101
19. Mahley R. W., Innerarity T. L., Weisgraber K. H. and Oh S. Y. (1979) Altered metabolism (in vivo and in vitro) of plasma lipoproteins after selective chemical modification of lysine residues of the apoproteins. J. Clin. Invest. 64: 743-750
20. Linton M. F., Gish R., Hul S. T., Butler E., Esquivel C., Bry W. I. et al. (1991) Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J. Clin. Invest. 88: 270-281
21. Boyles J. K., Pitas R. E., Wilson E., Mahley R. W. and Taylor J. M. (1985) Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J. Clin. Invest. 76: 1501-1513
22. Pitas R. E., Boyles J. K., Lee S. H., Foss D. and Mahley R. W. (1987) Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim. Biophys. Acta 917: 148-161
23. Pfrieger F. W. (2003) Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes? Bioessays 25: 72-78
24. Weisgraber K. H. (1994) Apolipoprotein E: Structure-function relationships. Adv. Protein Chem. 45: 249-302
25. Mahley R. W. and Rall S. C. Jr (1995) Type III hyperlipoproteinemia: the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: The Metabolic and Molecular Bases of Inherited Disease, 7th edn, pp. 1953-1980, Scriver C. R., Beaudet A. L., Sly W. S. and Valle D. (eds), McGraw-Hill, New York
26. Mahley R. W., Huang Y. and Rall S. C. Jr (1999) Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries and paradoxes. J. Lipid Res. 40: 1933-1949
27. Merched A., Blain H., Visvikis S., Herbeth B., Jeandel C. and Siest G. (1997) Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer's disease. J. Neurol. Sci. 145: 33-39
28. DeMattos R. B., Brendza R. P., Heuser J. E, Kierson M., Cirrito J. R., Fryer J. et al. (2001) Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice. Neurochem. Int. 39: 415-425
29. Pitas R. E., Boyles J. K., Lee S. H., Hui D. and Weisgraber K. H. (1987) Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B, E (LDL) receptors in the brain. J. Biol. Chem. 262: 14352-14360
30. Lomnistski L., Oron L., Sklan D. and Michaelson D. M. (1999) Distinct alterations in phospholipid metabolism in brains of apolipoprotein E-deficient mice. J. Neurosci. Res. 58: 586-592
31. Han X., Cheng H., Fryer D. J., Fagan A. M. and Holtzman D. M. (2003) Novel role for apolipoprotein E in the central nervous system: modulation of sulfatide content. J. Biol. Chem. 278: 8043-8051
32. Horsburgh K., McCarron M. O., White F. and Nicoll J. A. R. (2000) The role of apolipoprotein E in Alzheimer's disease, acute brain injury and cerebrovascular disease: evidence of common mechanisms and utility of animal models. Neurobiol. Aging 21: 245-255
33. Mahley R. W. and Rall S. C. Jr (2000) Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genom. Hum. Genet. 1: 507-537
34. Ignatius M. J., Shooter E. M., Pitas R. E. and Mahley R. W. (1987) Lipoprotein uptake by neuronal growth cones in vitro. Science 236: 959-962
35. Nathan B. P., Bellosta S., Sanan D. A., Weisgraber K. H., Mahley R. W. and Pitas R. E. (1994) Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 264: 850-852
36. Holtzman D. M., Pitas R. E., Kilbridge J., Nathan B., Mahley R. W., Bu G. et al. (1995) Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. Proc. Natl. Acad. Sci. USA 92: 9480-9484
37. Buttini M., Orth M., Bellosta S., Akeefe H., Pitas R. E., Wyss-Coray T. et al. (1999) Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: isoform-specific effects on neurodegeneration. J. Neurosci. 19: 4867-4880
38. Boyles J. K., Notterpek L. M. and Anderson L. J. (1990) Accumulation of apolipoproteins in the regenerating and remyelinating mammalian peripheral nerve. Identification of apolipoprotein D, apolipoprotein A-IV, apolipoprotein E and apolipoprotein A-I. J. Biol. Chem. 265: 17805-17815
39. Masliah E., Mallory M., Ge N., Alford M., Veinbergs I. and Roses A. D. (1995) Neurodegeneration in the central nervous system of apoE-deficient mice. Exp. Neurol. 136: 107-122
40. Poirier J., Baccichet A., Dea D. and Gauthier S. (1993) Cholesterol synthesis and lipoprotein reuptake during synaptic remodeling in hippocampus in adult rats. Neuroscience 55: 81-90
41. de Chaves E. I. P., Vance D. E., Campenot R. B., Kiss R. S., and Vance J. E. (2000) Uptake of lipoproteins for axonal growth of sympathetic neurons. J. Biol. Chem. 275: 19883-19890
42. Popko B., Goodrum J. F., Bouldin T. W., Zhang S. H. and Maeda N. (1993) Nerve regeneration occurs in the absence of apolipoprotein E in mice. J. Neurochem. 60: 1155-1158
43. Strittmatter W. J. and Roses A. D. (1996) Apolipoprotein E and Alzheimer disease. Annu. Rev. Neurosci. 19: 53-77
44. Weisgraber K. H. and Mahley R. W. (1996) Human apolipoprotein E: the Alzheimer's disease connection. FASEB J. 10: 1485-1494
45. Wisniewski T. and Frangione B. (1992) Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci. Lett. 135: 235-238
46. Strittmatter W. J., Weisgraber K. H., Huang D. Y., Dong L., Salvesen G. S., Pericak-Vance M. et al. (1993) Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 90: 8098-8102
47. Bales K. R., Verina T., Dodel R. C., Du Y., Altstiel L., Bender M. et al. (1997) Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 17: 263-264
48. Holtzman D. M., Bales K. R., Tenkova T., Fagan A. M., Parsadanian M., Sartorius L. J. et al. (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 97: 2892-2897
49. DeMattos R. B., Cirrito J. R., Parsadanian M., May P. C., O'Dell M. A., Taylor J. W. et al. (2004) ApoE and clusterin cooperatively suppress Aβ levels and deposition: evidence that ApoE regulates extracellular Aβ metabolism in vivo. Neuron 41: 193-202
50. Nicoll J. A., Roberts G. W. and Graham D. I. (1995) Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury. Nat. Med. 1: 135-137
51. Teasdale G. M., Nicoll J. A., Murray G. and Fiddes M. (1997) Association of apolipoprotein E polymorphism with outcome after head injury. Lancet 350: 1069-1071
52. Friedman G., Froom P., Sazbon L., Grinblatt I., Shochina M., Tsenter J. et al. (1999) Apolipoprotein E-epsilon4 genotype predicts a poor outcome in survivors of traumatic brain injury. Neurology 52: 244-248
53. Nathoo N., Chetty R., van Dellen J. R. and Barnett G. H. (2003) Genetic vulnerability following traumatic brain injury: the role of apolipoprotein E. Mol. Pathol. 56: 132-136
54. Alberts M. J., Graffagnino C., McClenny C., DeLong D., Strittmatter W., Saunders A. M. et al. (1995) ApoE genotype and survival from intracerebral haemorrhage. Lancet 346: 575
55. McCarron M. O., Hoffmann K. L., DeLong D. M., Gray L., Saunders A. M. et al. (1999) Intracerebral hemorrhage outcome: apolipoprotein E genotype, hematoma and edema volumes. Neurology 53: 2176-2179
56. Slooter A. J., Tang M. X., van Duijn C. M., Stern Y., Ott A., Bell K. et al. (1997) Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation. J. Am. Med. Assoc. 277: 818-821
57. Zarepesi S., Kaye J., Camicioli R., Grimslid H., Oken B., Litt M. et al. (1997) Modulation of the age at onset of Parkinson's disease by apolipoprotein E genotype. Ann. Neurol. 42: 655-658
58. Boyles J. K., Zoellner C. D., Anderson L. J., Kosik L. M., Pitas R. E., Weisgraber K. H. et al. (1989) A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J. Clin. Invest. 83: 1015-1031
59. Goodrum J. F. (1991) Cholesterol from degenerating nerve myelin becomes associated with lipoproteins containing apolipoprotein E. J. Neurochem. 56: 2082-2086
60. Handelmann G. E., Boyles J. K., Weisgraber K. H., Mahley R. W. and Pitas R. E. (1992) Effects of apolipoprotein E, beta-very low density lipoproteins and cholesterol on the extension of neurites by rabbit dorsal root ganglion neurons in vitro. J. Lipid Res. 33: 1677-1688
61. Kowal R. C., Herz J., Goldstein J. L., Esser V. and Blown M. S. (1989) Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc. Natl. Acad. Sci. USA 86: 5810-5814
62. Han X. and Gross R. W. (2003) Global analysis of cellular lipidomes directly from crude extracts of biological samples by ESI mass spectrometry: a bridge to lipidomics. J. Lipid Res. 44: 1071-1079
63. Han X. and Gross R. W. (2004) Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of the cellular lipidomes directly from crude extracts of biological samples. Mass Spec. Rev., in press
64. Svennerholm L., Bostrom K., Fredman P., Jungbjer B., Mansson J. E. and Rynmark B. M. (1992) Membrane lipids of human peripheral nerve and spinal cord. Biochim. Biophys. Acta 1128: 1-7
65. Vos J. P., Lopes-Cardozo M. and Gadella B. M. (1994) Metabolic and functional aspects of sulfogalactolipids. Biochim. Biophys. Acta 1211: 125-149
66. Krieger M. and Herz J. (1994) Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Ann. Rev. Biochem. 63: 601-637
67. Merrill Jr. A. H., Schmelz E.-M., Dillehay D. L., Spiegel S., Shayman J. A., Schroeder J. J. et al. (1997) Sphingolipids - the enigmatic lipid class: biochemistry, physiology and pathophysiology. Toxicol. Appl. Pharmacol. 142: 208-225
68. Ishizuka I. (1997) Chemistry and functional distribution of sulfoglycolipids. Prog. Lipid Res. 36: 245-319
69. von Figura K., Gieselmann V. and Jaeken J. (2001) Metachromatic leukodystrophy: Lysosomal disorders. In: The Metabolic and Molecular Bases of Inherited Diseases, Scriver C. R., Beaudet A. L., Sly W. S. and Valle D. (eds), 8th edn, pp. 3695-3724, McGraw-Hill, New York
70. Bosio A., Binczek E. and Stoffel W. (1996) Functional breakdown of the lipid bilayer of the myelin membrane in central and peripheral nervous system by disrupted galactocerebroside synthesis. Proc. Natl. Acad. Sci. USA 93: 13280-13285
71. Coetzee T., Fujita N., Dupree J., Shi R., Blight A., Suzuki K. et al. (1996) Myelination in the absence of galactocerebroside and sulfatide: normal structure with abnormal function and regional instability. Cell 86: 209-219
72. Bosio A., Büssow H., Adam J. and Stoffel W. (1998) Galactosphingolipids and axono-glial interaction in myelin of the central nervous system. Cell Tissue Res. 292: 199-210
73. Coetzee T., Suzuki K. and Popko B. (1998) New perspectives on the function of myelin galactolipids. Trends Neurosci. 21: 126-130
74. Saunders A. M., Strittmatter W. J., Schmechel D., St. George-Hyslop P. H., Pericak-Vance M. A., Joo S. H. et al. (1993) Association of apolipoprotein E allele le e4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43: 1467-1472
75. Poirier J., Davignon J., Bouthillier D., Kogan S., Bertrand P. and Gauthier S. (1993) Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 342: 697-699
76. Han X., Holtzman D. M., McKeel D. W. Jr, Kelley J. and Morris J. C. (2002) Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J. Neurochem. 82: 809-818
77. Han X., Fagan A. M., Cheng H., Morris J. C., Xiong C. and Holtzman D. M. (2003) Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Ann. Neurol. 54: 115-119
78. Cheng H., Xu J., McKeel D. W. Jr and Han X. (2003) Specificity and potential mechanism of sulfatide deficiency in Alzheimer's disease: an electrospray ionization mass spectrometric study. Cell. Mol. Biol. 49: 809-818
79. Tarkowski E., Tullberg M., Fredman P. and Wikkelsoe C. (2003) Correlation between intrathecal sulfatide and TNF-a levels in patients with vascular dementia. Dement. Geriat. Cogn. Disord. 15: 207-211
80. Zalc B., Monge M., Dupouey P., Hauw J. J. and Baumann N. A. (1981) Immunohistochemical localization of galactosyl and sulfogalactosyl ceramide in the brain of the 30-day-old mouse. Brain Res. 211: 341-354
81. Berntson Z., Hansson E., Ronnback L. and Fredman P. (1998) Intracellular sulfatide expression in a subpopulation of astrocytes in primary cultures. J. Neurosci. Res. 52: 559-568
82. Todderud G., Alford J., Millsap K. A., Aruffo A. and Tramposch K. M. (1992) PMN binding to P-selectin is inhibited by sulfatide. J. Leukocyte Biol. 52: 85-88
83. Suzuki Y., Toda Y., Tamatani T., Watanabe T., Suzuki T., Nakao T. et al. (1993) Sulfated glycolipids are ligands for a lymphocyte homing receptor, L-selectin (LECAM-1), binding epitope in sulfated sugar chain. Biochem. Biophys. Res. Commun. 190: 426-434
84. Bajorath J., Hollenbaugh D., King G., Harte W. Jr, Eustice D. C., Darveau R. P. et al. (1994) CD62/P-selectin binding sites for myeloid cells and sulfatides are overlapping. Biochemistry 33: 1332-1339
85. Kajihara J., Ye G., Kato K. and Suzuki Y. (1995) Sulfatide, a specific sugar ligand for L-selectin, blocks CC14-induced liver inflammation in rats. Biosci. Biotechnol. Biochem. 59: 155-157
86. Mulligan M. S., Miyasaka M., Suzuki M., Kawashima H., Lizuka M., Hasegawa A. et al. (1995) Anti-inflammatory effects of sulfatides in selectin-dependent acute lung injury. Int. Immunol. 7: 1107-1113
87. Bowman K. G., Cook B. N., de Graffenried C. L. and Bertozzi C. R. (2001) Biosynthesis of L-selectin ligands: sulfation of sialyl Lewis x-related oligosaccharides by a family of Glc-NAc-6-sulfotransferases. Biochemistry 40: 5382-5391
88. Merten M. and Thiagarajan P. (2001) Role for sulfatides in platelet aggregation. Circulation 104: 2955-2960
89. Marinier A., Martel A., Banville J., Bachand C., Remillard R., Lapointe P. et al. (1997) Sulfated galactocerebrosides as potential antiinflammatory agents. J. Med. Chem. 40: 3234-3247
90. Laskowitz D., Goel S., Bennett E. R. and Matthew W. D. (1997) Apolipoprotein E suppresses glial cell secretion of TNFα. J. Neuroimmunol. 76: 70-74
91. Finch C. E. and Sapolsky R. M. (1999) The evolution of Alzheimer's disease, the reproductive schedule and apoE isoforms. Neurobiol. Aging 20: 407-428
92. Dallongeville J., Lussier-Cacan S. and Davignon J. (1992) Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J. Lipid Res. 33: 447-454
93. Utermann G. (1987) Apolipoprotein E polymorphism in health and disease. Am. Heart J. 113: 433-440
94. Hallman D. M., Boerwinkle E., Saha N., Sandholzer C., Menzel H. J., Csazar A. et al. (1991) The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am. J. Hum. Genet. 49: 338-349
95. Roheim P. S., Carey M., Forte T. and Vega G. L. (1979) Apolipoproteins in human cerebrospinal fluid. Proc. Natl. Acad. Sci. USA 76: 4646-4649
96. Montine T. J., Montine K. S. and Swift L. L. (1997) Central nervous system lipoproteins in Alzheimer's disease. Am. J. Pathol. 151: 1571-1575
97. Montine K. S., Bassett C. N., Ou J. J., Markesbery W. R., Swift L. L. and Montine T. J. (1998) Apolipoprotein E allelic influence on human cerebrospinal fluid apolipoproteins. J. Lipid Res. 39: 2443-2451
98. Rebeck G. W., Alonzo N. C., Berezovska O., Harr S. D., Knowles R. B., Growdon J. H. et al. (1998) Structure and functions of human cerebrospinal fluid lipoproteins from individuals of different APOE genotypes. Exp. Neurol. 149: 175-182
99. Guyton J. R., Miller S. E., Martin M. E., Khan W. A., Roses A. D. and Strittmatter W. J. (1998) Novel large apolipoprotein E-containing lipoproteins of density 1.006-1.060 g/ml in human cerebrospinal fluid. J. Neurochem. 70: 1235-1240
100. Mulder M., Ravid R., Swaab D. F., de Kloet E. R., Haasdijk E. D., Julk J. et al. (1998) Reduced levels of cholesterol, phospholipids and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4. Alz. Dis. Assoc. Disord. 12: 198-203
101. Yamauchi K., Tozuka M., Hidaka H., Hidaka E., Kondo Y. and Katsuyama T. (1999) Characterization of apolipoprotein E-containing lipoproteins in cerebrospinal fluid: effect of phenotype on the distribution of apolipoprotein E. Clin. Chem. 45: 1431-1438
102. Yamauchi K., Tozuka M., Nakabayashi T., Sugano M., Hidaka H., Kondo Y. et al. (1999) Apolipoprotein E in cerebrospinal fluid: relation to phenotype and plasma apolipoprotein E concentrations. Clin. Chem. 45: 497-504
103. Fagan A. M., Younkin L. H., Morris J. C., Fryer J. D., Cole T. G., Younkin S. G. et al. (2000) Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Ann. Neurol. 48: 201-210
104. Eckert G. P., Kirsch C. and Mueller W. E. (2001) Differential effects of lovastatin treatment on brain cholesterol levels in normal and ApoE-deficient mice. Neuroreport 12: 883-887
105. Hayashi H., Igbavboa U., Hamanaka H., Kobayashi M., Fujita S. C., Wood W. G. et al. (2002) Cholesterol is increased in the exofacial leaflet of synaptic plasma membranes of human apolipoprotein E4 knock-in mice. Neuroreport 13: 383-386
106. Kirsch C., Eckert G. P., Koudinov A. R. and Mueller W. E. (2003) Brain cholesterol, statins and Alzheimer's Disease. Pharmacopsychiatry 36 (Suppl. 2): S113-S119
107. Rowland D. S., Trusko S. P., Savage M. J., Reaume A. G., Lang D. M., Hirsch J. D. et al. (1998) Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol. J. Biol. Chem. 273: 16576-16582
108. Refolo L. M., Pappolla M. A., Malester B., LaFrancois J., Bryant-Thomas T., Wang R. et al. (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7: 321-331
109. Levin-Allerhand J. A., Lominska C. E. and Smith J. D. (2002) Increased amyloid-levels in APPSWE transgenic mice treated chronically with a physiological high-fat high-cholesterol diet. J. Nutr. Health Aging 6: 315-319
110. Tietz A., Oron L., Mazliah E. and Michaelson D. M. (2002) The effects of apolipoprotein E genotype on brain lipid metabolism. Adv. Behav. Biol. 51: 33-38
111. Mauch D. H., Naegler K., Schumacher S., Goertzz C., Mueller E.-C., Otto A. et al. (2001) CNS synaptogenesis promoted by glia-derived cholesterol. Science 294: 1354-1357
112. Pfrieger F. W. (2003) Cholesterol homeostasis and function in neurons of the central nervous system. Cell. Mol. Life Sci. 60: 1158-1171
113. Dietschy J. M. and Turley S. D. (2001) Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 12: 105-112
114. Michikawa M., Fan Q.-W., Isobe I. and Yanagisawa K. (2000) Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J. Neurochem. 74: 1008-1016
115. Gong J.-S., Kobayashi M., Hayashi H., Zou K., Sawamura N., Fujita S. C. et al. (2002) Apolipoprotein E (apoE) isoform-dependent lipid release from astrocytes prepared from human apoE3 and apoE4 knock-in mice. J. Biol. Chem. 277: 29919-29926
116. Montine T. J, Montine K. S., Olson S. J., Graham D. G., Roberts L. J. II., Morrow J. D. et al. (1999). Increased cerebral cortical lipid peroxidation and abnormal phospholipids in aged homozygous apoE-deficient C57BL/6J mice. Exp. Neurol. 158: 234-241
117. Igbavboa U., Hamilton J., Kim H.-Y., Sun G. Y. and Wood W. G. (2002) A new role for apolipoprotein E: modulating transport of polyunsaturated phospholipid molecular species in synaptic plasma membranes. J. Neurochem. 80: 255-261
118. Han X., Holtzman D. M. and McKeel D. W. Jr (2001) Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J. Neurochem. 77: 1168-1180
119. Poirier J., Hess M., May P. C. and Finch C. E. (1991) Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning. Brain Res. Mol. Brain Res. 11: 97-106
120. Stone D. J., Rozovsky I., Morgan T. E., Anderson C. P., Hajian H. and Finch C. E. (1997) Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro. Exp. Neurol. 143: 313-318
121. Stoll G., Meuller H. W., Trapp B. D. and Griffin J. W. (1989) Oligodendrocytes but not astrocytes express apolipoprotein E after injury of rat optic nerve. Glia 2: 170-176
122. Nakai M., Kawamata T., Taniguchi T., Maeda K. and Tanaka C. (1996) Expression of apolipoprotein E mRNA in rat microglia. Neurosci. Lett. 211: 41-44
123. Xu P. T., Gilbert J. R., Qiu H. L., Rothrock-Christian T., Settles D. L., Roses A. D. et al. (1998) Regionally specific neuronal expression of human APOE gene in transgenic mice. Neurosci. Lett. 246: 65-68